<DOC>
	<DOCNO>NCT02505126</DOCNO>
	<brief_summary>The study evaluate efficacy 1 week tDCS ( 5 session ) placebo reduce alcohol consumption within 24 week follow treatment non-abstinent patient alcohol use disorder versus placebo .</brief_summary>
	<brief_title>A Clinical Trial Efficacy tDCS ) Reducing Alcohol Consumption Non-abstinent Patients ( REDSTIM )</brief_title>
	<detailed_description>340 patient expect randomized two group : 170 patient active tDCS 170 patient placebo tDCS Visit 1 : Patients receive one daily session ( 13:20:13 ) 5 consecutive day : current flow continuously twice 13min rest interval ( stimulation ) 20 min . Visit 1 7 : Change baseline week 24 Total Alcohol Consumption ( TAC ) Number Heavy Drinking Days ( HDD ) evaluate group . Evaluation alcohol consumption ( daily drinking diary , alcohol crave severity ) assessment like mood , quality life , safety . The co-primary outcome change baseline total alcohol consumption AND reduction number heavy drinking day 6 month treatment association tDCS analyze intention-to-treat principle use mixed model repeat measure ( 8 time ) .</detailed_description>
	<mesh_term>Alcohol Drinking</mesh_term>
	<mesh_term>Alcoholic Intoxication</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<criteria>Patients must sign date informed consent form Male female patient 18 year age Patients meet criterion Alcohol Use Disorder define Diagnostic statistical Manual mental disorder ( DSM5 ) Patients motivate reduce alcohol consumption At least one attempt achieve abstinence ( unsuccessful relapse ) Synopsis Selection subject • INCLUSION CRITERIA Suppression de : Patients high high level total alcohol consumption baseline ( H &gt; 60g/d ; F &gt; 40g/d ) , • NONINCLUSION CRITERIA &lt; 6 heavy drinking day 4 week randomization ( European Medicines Agency , 2010 ; day alcohol consumption ≥ 60 g men ≥40 g woman ) An average alcohol consumption medium risk level accord World health Organization ( WHO ) 4 week screen ( WHO , 2000 ; ≤40g/day men ; ≤20g/day woman ) , Patients refuse sign `` safety '' agreement Breathalcohol concentration &gt; 0 milligram per litre exhale air randomization ( visit 1 ) More 3days abstinence prior screen randomization ( screen visit visit 1 ) Concomitant treatment disulfiram , acamprosate , topiramate , baclofen , naltrexone , nalmefene History predelirium tremens delirium tremens A Revised Clinical Institute Withdrawal Assessment Alcohol score ≥ 10 ( indicate need medication support detoxification ) randomization ( visit 1 ) History epilepsy DSM5 substance use disorder alcohol nicotine use disorder Acute psychiatric disorder require hospitalisation and/or immediate adjustment psychotropic medication Major depression , define Hamilton Depression ( HAMD ) scale great equal 17 Recent change psychotropic medication ( &lt; 1 month ) Severe chronic psychiatric disorder include schizophrenia , paranoia bipolar disorder type I II Advanced liver , kidney , cardiac , pulmonary disease acute serious unstable medical condition would compromise patient 's participation study accord physician 's judgment Contraindications tDCS : metal head , implanted brain medical device Women pregnant lactate Women childbearing potential positive urine βhuman chorionic gonadotrophin pregnancy test randomization ( visit 1 ) Concurrent participation trial Employees investigator trial site Patients protected law Persons cover national health insurance Patients , opinion investigation , able complete TLFB complete daily alcohol consumption diary ( derive TLFB ) 3 month study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>